From the dualistic classification that divides endometrial cancer (EC) into two types with distinct underlying molecular profiling, histopathology and clinical behavior, arises a deeper understanding of the carcinogenesis pathways. EC treatment comprises different and multimodal therapeutic approaches, such as chemotherapy, radiation therapy or combinations of novel drugs; however, few of these regimens have truly improved progression-free or survival rates in advanced and metastatic settings.
Amadio, G., Masciullo, V., Ferrandina, M. G., Scambia, G., Emerging drugs for endometrial cancer, <<EXPERT OPINION ON EMERGING DRUGS>>, 2014; 19 (4): 497-509. [doi:10.1517/14728214.2014.971752] [http://hdl.handle.net/10807/67133]
Emerging drugs for endometrial cancer
Amadio, Giulia;Masciullo, Valeria;Ferrandina, Maria Gabriella;Scambia, Giovanni
2014
Abstract
From the dualistic classification that divides endometrial cancer (EC) into two types with distinct underlying molecular profiling, histopathology and clinical behavior, arises a deeper understanding of the carcinogenesis pathways. EC treatment comprises different and multimodal therapeutic approaches, such as chemotherapy, radiation therapy or combinations of novel drugs; however, few of these regimens have truly improved progression-free or survival rates in advanced and metastatic settings.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
